"In Cancer-Drug Study, More Wasn't Better"
Daniel Horowitz
Tuesday, 10 February 2009 17:31 UTC
http://online.wsj.com/article/SB123377952690248919.html?mod=loomia&loomia_si=t0:a16:g2:r1:c0.121226:b0
Combining two targeted drugs made the cancer “worse.”
-
Replies
-
This is actually the second study in colorectal cancer of cytotoxic chemo + an EGFR antibody + an anti-angiogenic drug showing that the addition of the anti-angio drug was worse than chemo + EGFR antibody without the anti-angiogenic drug. Unfortunately, they didn’t do any experiments to figure out why the combination therapy failed.
Hecht, J.R. et al. A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer. J Clin Oncol 27, 672-80 (2009).
Tol, J. et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 360, 563-72 (2009).
-
